Bold Therapeutics Presents Late-Breaking Poster on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025

VANCOUVER, BC, April 30, 2025 /PRNewswire/ -- Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, today announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, is presenting a late-breaking poster on BOLD-100's...